Multiple Sclerosis: Side Effects of Interferon Beta Therapy and Their Management

Overview

Journal Neurology

Specialty Neurology

Date 1999 Nov 24

PMID 10563602

Citations 83

Authors

E U Walther

R Hohlfeld

Affiliations

Soon will be listed here.

Abstract

Article abstract-Interferon beta (IFNbeta) reduces the relapse rate, disease activity as measured by serial MRI scanning, and disease progression of MS. Therapy with IFNbeta may be associated with a number of adverse reactions. Relatively frequent side effects include flu-like symptoms, transient laboratory abnormalities, menstrual disorders, and increased spasticity. Dermal injection site reactions occur after subcutaneous application of IFNbeta-1b and IFNbeta-1a. Possible side effects of IFNbeta include various autoimmune reactions, capillary leak syndrome, anaphylactic shock, thrombotic-thrombocytopenic purpura, insomnia, headache, alopecia, and depression. We discuss the mechanisms and management of the different side effects of IFNbeta.

Citing Articles

NET formation-mediated in situ protein delivery to the inflamed central nervous system.

Wu Y, Park J, Le Q, Byun J, Choi J, Xu E Nat Commun. 2024; 15(1):10747.

PMID: 39737919 PMC: 11686318. DOI: 10.1038/s41467-024-54817-7.

Understanding the role of potential biomarkers in attenuating multiple sclerosis progression via multiomics and network-based approach.

Shriwash N, Aiman A, Singh P, Basir S, Shamsi A, Shahid M PLoS One. 2024; 19(12):e0314428.

PMID: 39700118 PMC: 11658499. DOI: 10.1371/journal.pone.0314428.

Association of thrombotic microangiopathy with interferon therapy for hepatitis B: a case report.

Wei S, Mei W, Wang Y J Med Case Rep. 2024; 18(1):321.

PMID: 38965631 PMC: 11225129. DOI: 10.1186/s13256-024-04635-8.

Secretion of functional interferon by the type 3 secretion system of enteropathogenic Escherichia coli.

Rostovsky I, Wieler U, Kuzmina A, Taube R, Sal-Man N Microb Cell Fact. 2024; 23(1):163.

PMID: 38824527 PMC: 11144349. DOI: 10.1186/s12934-024-02397-y.

Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.

Muller J, Roos I, Kalincik T, Lorscheider J, Galli E, Benkert P Brain Behav. 2024; 14(5):e3498.

PMID: 38688877 PMC: 11061202. DOI: 10.1002/brb3.3498.